Lupin has informed that it has enclosed press release on 10th March 2021 as regards launch of the authorized generic version of Alinia (nitazoxanide) Tablets, 500 mg of Romark Laboratories, L.C. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.